NITE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NITE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-25), Nightstar Therapeutics's share price is $25.41. Nightstar Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2019 was $-1.57. Hence, Nightstar Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Nightstar Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:
Nightstar Therapeutics's Cash Flow from Operations per share for the three months ended in Mar. 2019 was $-0.35. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2019 was $-1.57.
The historical data trend for Nightstar Therapeutics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nightstar Therapeutics Annual Data | |||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | |||||
Price-to-Operating-Cash-Flow | - | - | - | - |
Nightstar Therapeutics Quarterly Data | |||||||||||
Dec15 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | |
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Nightstar Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Nightstar Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Nightstar Therapeutics's Price-to-Operating-Cash-Flow falls into.
Nightstar Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 25.41 | / | -1.566 | |
= |
Nightstar Therapeutics's Share Price of today is $25.41.
Nightstar Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.57.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of Nightstar Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Nea 15 Gp, Llc | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
David Charles Lubner | director | C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472 |
Gregory Scott Robinson | officer: Chief Scientific Officer | NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453 |
James G Mcarthur | director | NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453 |
Senthil Vel Sundaram | officer: Chief Financial Officer | NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453 |
Tuyen Ong | officer: Chief Development Officer | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Paula K Cobb | director | NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453 |
Mohamad Makhzoumi | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Scott M Whitcup | director | 2525 DUPONT DRIVE, IRVINE CA 92612 |
Scott D Sandell | 10 percent owner | |
Nea Partners 15, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
New Enterprise Associates 15, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Florence Anthony A. Jr. | 10 percent owner | 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815 |
Peter W. Sonsini | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Forest Baskett | 10 percent owner |
From GuruFocus
By Marketwired Marketwired • 06-05-2019
By Marketwired Marketwired • 09-28-2018
By Marketwired Marketwired • 04-04-2018
By Marketwired Marketwired • 05-08-2019
By Marketwired Marketwired • 09-22-2018
By Marketwired Marketwired • 09-13-2018
By Marketwired Marketwired • 06-07-2019
By GlobeNewswire GlobeNewswire • 04-03-2018
By Marketwired Marketwired • 08-13-2018
By Marketwired Marketwired • 04-26-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.